Clinical trials: Premenopausal
Breast Cancer
Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. 4-hydroxytamoxifen gel (a substance made when tamoxifen breaks down in the body) may be effective in…
- Trial name
- NCT00084344
- Testing
- 4-hydroxytamoxifen, breast imaging study, radiomammography
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwestern University
Hormone Receptor-Positive Breast Cancer
Estradiol Levels According to Body Mass Index in Premenopausal Patients With Breast Cancer
his prospective observational study will evaluate whether body mass index (BMI) is associated with serum estradiol levels in premenopausal women with hormone receptor-positive breast cancer.
- Trial name
- SIMPEC-E2 (NCT07833501)
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- D'Or Institute for Research and Education
Uterine Fibroids, Heavy Menstrual Bleeding
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in…
- Trial name
- NCT02654054
- Testing
- Elagolix, Estradiol/Norethindrone Acetate
- Where
- 96 sites in United States, Canada and 1 more
- Volunteers
- 413 people
- Sponsor
- AbbVie
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00253539
- Testing
- arzoxifene hydrochloride, tamoxifen citrate
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic
Iron-deficiency
Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed IHAT (iron hydroxide adipate tartrate) at 2 different doses compared to placebo for increasing serum ferritin levels in iron-deficient but…
- Trial name
- NCT05950841
- Testing
- Low dose IHAT, High Dose IHAT, Carob flour
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- RDC Clinical Pty Ltd
Premenstrual Syndrome, Menstrual Discomfort
A Clinical Trial to Evaluate the Effects of the Kaia Relief - Cycle System on Premenstrual Symptom Severity, Menstrual Discomfort, and Overall Well-Being in Premenopausal Women.
This is a single-group, open-label, decentralized clinical trial evaluating the effects of the Kaia Relief - Cycle System (a commercial dietary supplement consisting of Day and Night capsules) on premenstrual symptom severity…
- Conditions
- Premenstrual Syndrome, Menstrual Discomfort, Premenstrual Symptoms
- Trial name
- NCT07876050
- Testing
- Kaia Relief - Cycle System (Day and Night)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Vivance Group
Dietary Modification
Green Vegetables and Women's Health
The 2010 Dietary Guidelines for Americans recommend that individuals consume 4.5 to 5 cups fruits and vegetables daily. However, at current intake levels, fruit consumption will have to improve by more than 100% and vegetable…
- Trial name
- NCT01726127
- Testing
- Broccoli and Brussels Sprouts, Cruciferous Complete
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Metastatic Breast Cancer, Estrogen Receptor Positive Tumor
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
Fulvestrant is an ER antagonist with no agonist effects, which binds, blocks and degrades the ER. Fulvestrant is comparable to third-generation aromatase inhibitors in terms of efficacy and tolerability for patients who have…
- Conditions
- Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal
- Trial name
- FLAG (NCT01266213)
- Testing
- Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Samsung Medical Center